Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a plasma beam stop anal lesions from becoming cancer?

NCT ID NCT00428285

Disease control Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase II trial is testing whether argon plasma coagulation (APC) can safely and effectively treat high-grade anal lesions (AIN 2/3) in HIV-positive men who have sex with men. APC uses ionized argon gas to deliver a controlled electrical current that destroys abnormal cells. The study will enroll 20 participants and assess how well the procedure clears the lesions, as well as its tolerability and safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Argon plasma coagulation (APC), a procedure that uses ionized argon gas to destroy abnormal cells in the anal lining.
What this could lead to
If effective, APC could offer a safe, well-tolerated treatment option to prevent anal cancer in HIV-positive men with high-grade lesions.
What could go wrong
This is a small pilot study with only 20 participants, so results may not apply broadly. The procedure may cause discomfort or side effects, and its long-term effectiveness is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

20 people

The number who actually took part.

Start date

Feb 2007

Finished

Jul 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-65 years * The last two High Resolution Anoscopies (HRA) of the patient, occurring at least 4 months apart, revealed histologic diagnoses of AIN 2 or 3 * HIV infected for at least 6 months * Patient must be a man having sex with other men (currently or anteriorly). * Able to provide a signed and dated Research Ethics Board (REB)-approved informed consent form (ICF) for the study Exclusion Criteria: * History of invasive anal cancer * International normalized ratio (INR) \> 1.5 * Platelet count \< 50,000 * Previously (or currently) received chemotherapy or radiotherapy for AIN or anal cancer * Currently receiving interferon or cidofovir treatment * Diagnosed with circumferential (diffuse) high-grade AIN, or involving \> 75% of the anal canal.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anus neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anus neoplasm HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anus neoplasms HIV infections

Contacts and locations

Locations

  • Notre-Dame Hospital (Centre Hospitalier de l'Université de Montréal)

    Montreal, Quebec, H2L 4M1, Canada

  • Royal Victoria Hospital (McGill University Health Center)

    Montreal, Quebec, H2X 2P4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.